Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Breast Cancer Research : BCR|July 5, 2014
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patientsRyuji Takahashi, Uhi Toh, Nobutaka Iwakuma, et al.Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|July 16, 2015
Effects of corticosteroids and hyaluronic acid on torn rotator cuff tendons in vitro and in ratsHidehiro Nakamura, Masafumi Gotoh, Tomonoshin Kanazawa, et al.Cancer Science|July 28, 2015
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 alleleShinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, et al.Cancer Science|February 9, 2017
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ alleleShinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, et al.Cancer Science|February 28, 2016
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patientsSatoru Iwasa, Yasuhide Yamada, Yuji Heike, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based ChemotherapyMasanori Noguchi, Kazumasa Matsumoto, Hirotsugu Uemura, et al.Cancer Immunology Research|October 30, 2014
Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancerShiro Kibe, Shigeru Yutani, Satoru Motoyama, et al.International Journal of Oncology|April 3, 2020
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patientsShigetaka Suekane, Shigeru Yutani, Akira Yamada, et al.Developmental and Comparative Immunology|April 16, 2013
Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseasesSatoko Matsueda, Nobukazu Komatsu, Kenichi Kusumoto, et al.Oncology Reports|March 3, 2018
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptidesShinsuke Kanekiyo, Shoichi Hazama, Hiroko Takenouchi, et al.Pageof 9